Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

 
• By Joseph Haas

Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.

Coronavirus with cardio lines, cellular designs and lungs
Oral antiviral shows ability to reduce risk of COVID-19 hospitalization and death

More from COVID-19

More from Scrip